Literature DB >> 15507723

Selective silencing of viral gene E6 and E7 expression in HPV-positive human cervical carcinoma cells using small interfering RNAs.

Ming Jiang1, Jo Milner.   

Abstract

The newly discovered phenomenon of RNA interference (RNAi) offers the dual facility of selective viral gene silencing coupled with ease of tailoring to meet genetic variation within the viral genome. Such promise identifies RNAi as an exciting new approach to treat virus-induced diseases, including virus-induced cancers. RNAi can be induced using small interfering RNA (siRNA). Synthetic siRNA targets homologous mRNA for degradation, and this process is highly efficient. Using cervical cancer cells as a model, we demonstrate RNAi for viral oncogenes. Cervical cancer is the second most common cancer in women worldwide and is caused by human papillomavirus (HPV). Silencing of HPV E6 and E7 gene expression was achieved using siRNAs to target the respective viral mRNAs. E6 silencing induced accumulation of cellular p53 protein, transactivation of the cell cycle control p21 gene, and reduced cell growth. By contrast, E7 silencing induced apoptotic cell death. HPV-negative cells appeared to be unaffected by the antiviral siRNAs. Thus siRNA can induce selective silencing of exogenous viral genes in mammalian cells, and the process does not interfere with the recovery of cellular regulatory systems previously inhibited by viral gene expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15507723     DOI: 10.1385/1-59259-848-x:401

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  9 in total

1.  Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions.

Authors:  Wei Feng; Xiuzhen Duan; Jinsong Liu; Jianguo Xiao; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2008-10-02

2.  Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers.

Authors:  J T-C Chang; T-F Kuo; Y-J Chen; C-C Chiu; Y-C Lu; H-F Li; C-R Shen; A-J Cheng
Journal:  Cancer Gene Ther       Date:  2010-10-01       Impact factor: 5.987

3.  Activation of the retinoblastoma tumor suppressor mediates cell cycle inhibition and cell death in specific cervical cancer cell lines.

Authors:  Ryan J Bourgo; Wesley A Braden; Susanne I Wells; Erik S Knudsen
Journal:  Mol Carcinog       Date:  2009-01       Impact factor: 4.784

4.  Retinoblastoma-independent antiproliferative activity of novel intracellular antibodies against the E7 oncoprotein in HPV 16-positive cells.

Authors:  Luisa Accardi; Maria Gabriella Donà; Anna M Mileo; Marco G Paggi; Antonio Federico; Paola Torreri; Tamara C Petrucci; Rosita Accardi; David Pim; Massimo Tommasino; Lawrence Banks; Barbara Chirullo; Colomba Giorgi
Journal:  BMC Cancer       Date:  2011-01-17       Impact factor: 4.430

5.  Leukemia inhibitory factor downregulates human papillomavirus-16 oncogene expression and inhibits the proliferation of cervical carcinoma cells.

Authors:  Joseph M Bay; Bruce K Patterson; Nelson N H Teng
Journal:  Infect Dis Obstet Gynecol       Date:  2011-06-04

Review 6.  Antiviral RNAi: translating science towards therapeutic success.

Authors:  Priya S Shah; David V Schaffer
Journal:  Pharm Res       Date:  2011-08-09       Impact factor: 4.200

7.  TALEN based HPV-E7 editing triggers necrotic cell death in cervical cancer cells.

Authors:  Sumitra Shankar; Deepti Prasad; Rahul Sanawar; Ani V Das; M Radhakrishna Pillai
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

Review 8.  RNA interference for antiviral therapy.

Authors:  Mali Ketzinel-Gilad; Yosef Shaul; Eithan Galun
Journal:  J Gene Med       Date:  2006-08       Impact factor: 4.565

9.  Antisense RNA directed to the human papillomavirus type 16 E7 mRNA from herpes simplex virus type 1 derived vectors is expressed in CaSki cells and downregulates E7 mRNA.

Authors:  Ilkka Kari; Stina Syrjänen; Bo Johansson; Piritta Peri; Bin He; Bernard Roizman; Veijo Hukkanen
Journal:  Virol J       Date:  2007-06-04       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.